cetuximab + lapatinib

Cetuximab + lapatinib is a combination therapy of two targeted anticancer agents used in clinical trials for the treatment of solid tumors, particularly those driven by overexpression or dysregulation of the epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/ErbB2). Cetuximab is a monoclonal antibody that binds to EGFR on cell surfaces, blocking ligand binding and inhibiting downstream signaling pathways involved in cell proliferation and survival. Lapatinib is an oral small molecule tyrosine kinase inhibitor that targets both EGFR (HER1/ERBB1) and HER2 (ERBB2), inhibiting their intracellular kinase activity. The combination has shown synergistic effects in preclinical models by reducing EGFR phosphorylation, decreasing cell surface EGFR expression, inducing apoptosis, and overcoming resistance to anti-EGFR therapies. Clinical studies have demonstrated tolerability with expected toxicities such as rash and diarrhea, as well as notable clinical activity in patients with prior anti-EGFR therapy exposure[1][2][3].

Other names

lapatinib and cetuximabcetuximab + lapatinib